CSIMarket
 


China Pharma Holdings Inc   (CPHI)
Other Ticker:  
 

Cumulative China Pharma Holdings Inc 's Total Debt to Equity for Trailing Twelve Months Period

CPHI's Total Debt to Equity for Trailing Twelve Months Period and Total Debt, Equity growth


Select the Comparisons : Select the Ratio:

CPHI Total Debt to Equity for Trailing Twelve Months Period

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Equity Growth 115.56 % 8.15 % -12.56 % -28.71 % -58.64 %
Y / Y Total Debt Growth -31.15 % -70.56 % -65.95 % -74.52 % 5.01 %
Total Debt to Equity for Trailing Twelve Months Period 0.57 0.77 1.15 1.47 1.72
Total Ranking # 1680 # 2067 # 2538 # 3061 # 3009
Seq. Equity Growth 40.4 % -6.78 % 8.84 % 51.33 % -29.56 %
Seq. Total Debt Growth 33.31 % -25.4 % 29.05 % -46.35 % -43.01 %


Total Debt to Equity for Trailing Twelve Months Period Comment for 12 Months ending at Sep 30 2023
On the trailing twelve months basis Despite net new borrowings of 33.31% China Pharma Holdings Inc managed to decrease Total Debt to Equity for Trailing Twelve Months Period in III. Quarter to 0.57, above China Pharma Holdings Inc 's average Total Debt to Equity for Trailing Twelve Months Period.
Total Debt to Equity for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies in Major Pharmaceutical Preparations industry 116 other companies have achieved lower Total Debt to Equity for Trailing Twelve Months Period than China Pharma Holdings Inc . While total ranking remained unchanged compare to previous quarter at no. .

What is Debt to Equity Ratio?
CPHI Charts and Quotes
Total Debt to Equity CPHI in the most recent quarter
Total Debt to Equity for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 117
Sector # 279
S&P 500 # 1565


Total Debt to Equity for Trailing Twelve Months Period Statistics
High Average Low
1.72 0.39 0.03
(Sep 30 2022)   (Sep 30 2017)




Companies with similar average Total Debt to Equity for Trailing Twelve Months Period for 12 months ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Total Debt to Equity for Trailing Twelve Months Period
Zoetis Inc   1.47 
Avadel Pharmaceuticals Plc  1.40 
Trevena inc   1.39 
Ionis Pharmaceuticals Inc  1.34 
Aveo Pharmaceuticals Inc   1.34 
Arcutis Biotherapeutics Inc   1.31 
Bristol myers Squibb Company  1.23 
G1 Therapeutics Inc   1.19 
Vbi Vaccines Inc  1.12 
Adc Therapeutics Sa  1.10 
Chembio Diagnostics Inc   1.06 
Catalent Inc   1.04 
Durect Corp  1.02 
Societal Cdmo Inc   1.01 
Biovie Inc   0.96 
Tempest Therapeutics Inc   0.96 
Nabriva Therapeutics Plc  0.94 
Emergent Biosolutions Inc   0.94 
Madrigal Pharmaceuticals Inc   0.94 
Viatris Inc   0.93 
Mirum Pharmaceuticals Inc   0.93 
Tg Therapeutics Inc   0.93 
Marinus Pharmaceuticals Inc   0.92 
Spectrum Pharmaceuticals Inc   0.90 
Corbus Pharmaceuticals Holdings Inc   0.88 
Coya Therapeutics Inc   0.87 
Journey Medical Corporation  0.87 
Perrigo Company Plc  0.86 
Prestige Consumer Healthcare Inc   0.86 
Elanco Animal Health Inc  0.86 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com